SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ:TVTX) today announced that the Company will present nine abstracts in rare kidney disease at the World Congress of Nephrology (WCN) in Buenos Aires, Argentina, on April 13-16, 2024, and the American Nephrology Nurses Association (ANNA) National Symposium in Orlando, Florida, on April 14-17, 2024.
At WCN, the Company will present subgroup analyses of the Phase 3 PROTECT Study of FILSPARI® (sparsentan) in IgA nephropathy (IgAN) showing the treatment effect across participants with different levels of baseline proteinuria. Encore presentations will include preliminary findings from the SPARTAN Study supportive of FILSPARI as a first-line treatment for patients with IgAN, as well as the early clinical experience from the PROTECT open-label extension regarding the addition of sodium-glucose cotransporter-2 inhibitors (SGLT2i) to ongoing FILSPARI treatment in patients with IgAN. At ANNA, the Company will present additional insights from the HONUS trial, including health-related quality of life (HRQoL) data and the humanistic burden experienced by patients with IgAN and focal segmental glomerulosclerosis (FSGS).
"The data we are presenting at WCN and ANNA reinforce the wealth of evidence supporting FILSPARI's profile to become an effective foundational treatment replacing RAAS inhibition, with the potential to reduce the lifetime risk of kidney failure for patients with IgAN," said Jula Inrig, M.D., chief medical officer of Travere Therapeutics. "We are also looking forward to presenting data that address broader aspects of disease management, building upon Travere's holistic approach to improving patient outcomes in RKD."
WCN Late Breaking Abstract
Sparsentan vs Irbesartan in Patients with Immunoglobulin A Nephropathy (IgAN): Subgroup Analyses of 2-Year Results from the Pivotal Phase 3 PROTECT Trial
Oral Presentation: MON-296
Late Breaking Clinical Trial Session
Exhibition Hall and Main Foyer; April 15, 2024, 3:35-3:45 p.m. ART
WCN Poster Presentations
Sparsentan as First-Line Treatment of Incident Patients with IgA Nephropathy: Preliminary Findings from the SPARTAN Trial
Poster: SUN-042
Poster Session: Clinical Glomerulonephritis 2
Exhibition Hall and Main Foyer; April 14, 2024, 5:45-6:45 p.m. ART
Concomitant Sparsentan and Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Patients with IgA Nephropathy (IgAN) in the PROTECT Open-Label Extension (OLE)
Poster: SUN-049
Poster Session: Clinical Glomerulonephritis 2
Exhibition Hall and Main Foyer; April 14, 2024, 5:45-6:45 p.m. ART
Sparsentan Receptor Occupancy Modeling, Clinical Actions, and Safety
Poster: SUN-045
Poster Session: Clinical Glomerulonephritis 2
Exhibition Hall and Main Foyer; April 14, 2024, 5:45-6:45 p.m. ART
Preliminary Findings from the Phase 2 EPPIK Study of Sparsentan in Pediatric Patients with Selected Proteinuric Glomerular Diseases
Poster: SUN-048
Poster Session: Clinical Glomerulonephritis 2
Exhibition Hall and Main Foyer; April 14, 2024, 5:45-6:45 p.m. ART
ANNA Poster Presentations
Sparsentan (SPAR), a Novel Non-immunosuppressive Therapy for Patients (pts) with Immunoglobulin A Nephropathy (IgAN): Pivotal Phase 3 PROTECT Trial Data
Exhibit Hall; April 15, 2024, 8:45-10:15 a.m. & 2:30-4 p.m.; April 16, 2024, 8:45-10:15 a.m. ET
Contextualizing the Humanistic Burdens of Focal Segmental Glomerular Sclerosis (FSGS) in HONUS Compared to External Controls in NHWS
Exhibit Hall; April 15, 2024, 8:45-10:15 a.m. & 2:30-4 p.m.; April 16, 2024, 8:45-10:15 a.m. ET
Indirect Comparisons of Humanistic Burdens Between Patients with Immunoglobulin A Nephropathy (IgAN) from HONUS and External Controls from NHWS
Exhibit Hall; April 15, 2024, 8:45-10:15 a.m. & 2:30-4 p.m.; April 16, 2024, 8:45-10:15 a.m. ET
Data in Kidney Failure (KF) Estimated by Treatment Effects on Proteinuria in Patients with Immunoglobulin A Nephropathy (IgAN)
Exhibit Hall; April 15, 2024, 8:45-10:15 a.m. & 2:30-4 p.m.; April 16, 2024, 8:45-10:15 a.m. ET
About IgA Nephropathy
IgA nephropathy (IgAN), also called Berger's disease, is a rare progressive kidney disease characterized by the buildup of immunoglobulin A (IgA), a protein that helps the body fight infections, in the kidneys. The deposits of IgA cause a breakdown of the normal filtering mechanisms in the kidney, leading to blood in the urine (hematuria), protein in the urine (proteinuria) and a progressive loss of kidney function. Other symptoms of IgAN may include swelling (edema) and high blood pressure.
IgAN is the most common type of primary glomerulonephritis worldwide and a leading cause of kidney failure due to glomerular disease. IgAN is estimated to affect up to 150,000 people in the U.S. and is one of the most common glomerular diseases in Europe and Japan.
About Travere Therapeutics
At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop and deliver life-changing therapies. ...